European Patent Office to Grant Patent for Macrocure’s CureXcell®
PETACH TIKVA, Israel, March 14, 2013 /PRNewswire/ –
Macrocure (http://www.macrocure.com), a biotechnology company developing advanced
cell therapy products, announced today that the European Patent Office (EPO) intends to
grant a European patent covering Marcocure’s flagship product, CureXcell(R). The patent
will be officially granted under an application titled “Activate Leukocyte Composition”
and will provide patent coverage for CureXcell(R) in Europe through March 2030.
CureXcell(R) is a novel approach to treating hard-to-heal wounds by replenishing the
imbalanced inflammatory environment in non-healing wounds with a broad array of
functionally-active allogeneic immune cells. These cells are superficially injected into
the wound bed, once a month, and release the necessary cytokines and growth factors for
the wound to heal.
About 5,000 patients with various types and severities of hard-to-heal wounds have
been treated in Israel. CureXcell(R) has been approved for reimbursement by the Israeli
Ministry of Health.
“The granting of a European patent for CureXcell(R) is a significant milestone for
MacroCure, which fits with our strategy to become a leader in the hard to heal wound
treatment market in Europe,” said Nissim Mashiach, President and CEO of Macrocure.
Macrocure is a biotechnology company which focuses on the development and
commercialization of advanced wound care therapies. Macrocure is pursuing regulatory
market approval in North America and Europe. CureXcell(R) is also currently undergoing a
Phase III randomized, double-blind trial for lower extremity chronic ulcers in adults with
diabetes under SPA in the United States, Canada and Israel. The product has marketing
authorization in Israel for the treatment of chronic ulcers, but is not yet licensed for
sale in either the United States or Canada.
Media Contact: Matthew Krieger Finn Partners Israel for Macrocure +972-544-676-950 firstname.lastname@example.org